header logo image


Page 795«..1020..794795796797..800810..»

Seasonally Decreased Immune Function Around the Holidays – Matthews Beacon

December 12th, 2019 4:55 pm

The human immune system is highly complex and multi-faceted. Seemingly an infinite number of things can affect our internal landscape and alter how our immune system defenses respond to and fight foreign invaders to keep us healthy. The misconception a lot of people have is thinking that we want a super active immune system that is like Rambo, an ultimate killing machine! Really what we want is a balanced immune system, that neither swings into hyperactivity nor falls into decreased function. If our immune system functions too high, we end up with autoimmune disorders this is when the immune system attacks our bodys cells, not just foreign invaders, if it is not functioning as it should, when exposed to germs we get sick and have to fight off an illness.

Did you know that just the time of year can affect our immune system function? Just the fact that the daylight does not last as long can cause our immune system to be less responsive. Shorter days and colder weather cause people to stay inside more, reducing the amount of natural vitamin D they make, which is a key immune system booster. An alternative for the individual not wanting to go outside is supplementing Vitamin D into their diet.

Read more here:
Seasonally Decreased Immune Function Around the Holidays - Matthews Beacon

Read More...

By turning stem cells into brain cells, Aspen Neuroscience hopes to rewind the progress of Parkinson’s disease – FierceBiotech

December 12th, 2019 4:55 pm

The idea of a cell therapy for Parkinsons disease starts out simple: Symptoms of the progressive disease are largely driven by the deaths of dopamine-producing neurons found deep within the brain. With lower levels of the neurotransmitter come the characteristic tremors, rigidity and slow movements.

By replacing those lost nerve cells with new dopamine producers, researchers hope to renew the brains connection to the bodys muscles and improve a persons overall motor function.

But in the brain, everything becomes more complicated. On top of the risk of immune system rejection that comes with any kind of living tissue transplant, its important to make sure the implanted cells function correctly and do not pick up any dangerous genetic mutations as they grow.

How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

Now, a new company, Aspen Neuroscience, aims to tackle both obstacles at once.

First, the startup hopes to avoid any harmful immune reactions by using a patients own cells as a starting point. Then, Aspen plans to implement a rigorous quality control program employing whole genome sequencing and artificial intelligence to make sure the cells stay in line as theyre processed and readied for the procedure.

And to do it, the San Diego-based company is starting out with $6.5 million in seed money plus an impressive roster of names.

They are led by neurology researcher Howard Federoff, previously vice chancellor for health affairs and CEO of the University of California, Irvine health system as well as the executive dean of medicine at Georgetown University. Hes joined by Aspen co-founder and stem cell scientist Jeanne Loring, founding director and professor emeritus of the Center for Regenerative Medicine at the Scripps Research Institute.

Meanwhile, the seed round was led by Domain Associates and Axon Ventures with additional backing from Alexandria Venture Investments, Arch Venture Partners, OrbiMed and Section 32.

Aspen looks to combine its expertise in stem cell biology, genomics and neurology to offer the first autologous cell therapy for Parkinsons diseasewhile others in the space have pursued allogeneic routes, or therapies derived from donors other than the patient.

The process starts with a culture of the patients skin cells, which are then genetically induced to become pluripotent stem cellsor cells capable of differentiating into any other cell type in the body. These are then chemically nudged further to transform into precursor versions of the dopamine-producing neurons, which are typically found in the midbrain and regions responsible for the movement of limbs.

We can say without any equivocation that we can produce the population of cells necessary to transplant, and in a short enough period of time to have a potential beneficial impact on the evolution of the disease, said Federoff, who has also served as chair of the NIHs Recombinant DNA Advisory Committee and helped lead the U.S. Parkinsons Disease Gene Therapy Study Group.

We envisage that this will set back the clock on patients who have Parkinsons, unlike any other therapy that we know of, he told FierceMedTech in an interview.

The number of cells needed would be much smaller compared to other cell therapies and cancer treatments. The healthy human brain contains only about 200,000 dopamine-producing nerve cells, split between its two hemispheres, while patients with Parkinsons disease have lost about 50% or more of those neurons.

Aspen aims to evaluate two doses: one that aims to replace about 60% to 65% of a persons normal cell complement and another larger treatment, Federoff said.

Those smaller doses, as well as starting with a patients donor cells, help make the treatment safer to produce by requiring fewer steps. Each cycle of cell division and multiplication to increase their numbers carries the risk of introducing genetic mutations.

As the cells are grown, they are consistently evaluated with data-driven techniques pioneered by Lorings laboratory. Using whole genome RNA sequencing, Aspen will match the cells up at every stage with a genetic barcode taken from each patient at the start. This will allow them to look for changes, duplications or deletions in the pluripotent stem cell genome.

If the cells harbor mutations that are cancer drivers, we don't want to put those into people, Loring said. The only way is to check the sequencing before we transplant them.

The cells used in the transplant procedure arent fully grown; as neuron progenitors, they mimic the development steps seen in the brain of a growing fetus after theyre placed in the body as they wire themselves up to other neural structures and begin to form new networks of their own.

We anticipate that they will manufacture and release dopamine in a manner that is consistent with synaptic neurotransmission and the process of communicating from cell-to-cell, said Federoff. They will take up dopamine from synapses when it has done its business, bring it back into the cell, and prepare it for another synaptic release.

These are not just dopamine pumps, theyre real neurons, added Loring. They will genuinely replace the cells that have been lost in every way.

Aspen plans to pursue two courses of therapy, for the two major types of Parkinsons disease. Their lead candidate is for idiopathic, or sporadic Parkinsons, while their second is a CRISPR-edited version of the therapy designed to address one of the diseases most common genetic mutations, linked to about 5% of cases.

This would not only aim to restart dopamine production in this orphan indication, but also restore the damaged enzyme GBA, which is seen as an underlying cause. Federoff and Loring expect their sequencing-based quality check system will also help catch any off-target edits linked to the use of CRISPR-Cas9.

The company has yet to secure permission from the FDA to officially launch clinical trials, but the agency has signed off on Aspens plans to prepare a trial-ready cohort of Parkinsons disease patients in the meantime. This would include the initial stages of recruitment and testing, including the selection of patients capable of having their skin cells made into pluripotent stem cells.

After it receives its go-ahead from the FDA, Aspen plans to hit the ground running,enrolling at least 176 participants in a phase 1/2 study that includes a randomized stage to determine clinical benefits.

Read more:
By turning stem cells into brain cells, Aspen Neuroscience hopes to rewind the progress of Parkinson's disease - FierceBiotech

Read More...

Father’s X chromosome may yield clues to higher rates of autoimmune disease in women – Newswise

December 12th, 2019 4:55 pm

MEDIA CONTACT

Available for logged-in reporters only

By Sarah C.P. Williams

Newswise UCLA scientists have discovered one reason why autoimmune diseases are more prevalent in women than in men. While males inherit their mothers X chromosome and fathers Y chromosome, females inherit X chromosomes from both parents. New research, which shows differences in how each of those X chromosomes is regulated, suggests that the X chromosome that females get from their father may help to explain their more active immune system.

Its been known for many years that women are more susceptible to autoimmune diseases than men are, said lead study author Dr. Rhonda Voskuhl, a UCLA professor of neurology and director of the UCLA Multiple Sclerosis Program who also holds the Jack H. Skirball Chair in Multiple Sclerosis Research. Figuring out why can help us develop new drugs to treat these autoimmune diseases.

Autoimmune diseases, such as multiple sclerosis and rheumatoid arthritis, are conditions that affect the bodys ability to fight viruses, bacteria and infections. The problem causes a persons immune cells to attack the body instead.

Women generally have stronger immune responses than men, with more robust responses to some vaccinations and infections. However, this heightened immune system also makes women three times more likely than men to develop multiple sclerosis, nine times more likely to develop lupus ,and more prone to a host of other autoimmune diseases, Voskuhl said. The effect of sex hormones testosterone and estrogen in these differences has been well-studied, but the role of sex chromosomes has been less clear.

In thenew work, published in Proceedings of the National Academy of Sciences, Voskuhl and her colleagues focused on differences between the X chromosomes inherited from each parent. They first analyzed expression levels of genes in mice with the male (XY) and female (XX) chromosome set. They identified a handful of immune system-related genes on the X chromosome that are expressed less producing fewer corresponding molecules in the immune cells of female mice.

To further study these differences, the Voskuhl team next compared mice that had just one X chromosome either a maternal or paternal X chromosome. They determined levels of methylation the addition of methyl chemical groups to DNA in the X chromosomes. Methylation is known to turn down, or block, the expression of genes. And while the methyl groups arent part of the DNA sequence itself, patterns of methylation can be passed from parent to child. The researchers discovered that there was more methylation on paternal than on maternal X chromosomes. Finally, they confirmed that several genes on the X chromosome were expressed less when the X chromosome was of paternal as compared to maternal origin.

What were talking about here is not mutations that affect gene sequences, but instead signals that affect how the same sequence of genes are differentially expressed in females versus males. These differences would be missed in traditional genetic studies, Voskuhl said.

The findings suggest that the X chromosomes packaged into sperm and passed from father to daughter may have higher levels of methylation than the X chromosomes passed along in eggs from a mother to her offspring. This methylation dampens the expression of some immune system genes in females, making their immune activity different from males.

If you can find regulators of methylation that target these differences, you might be able to reduce the immune responses of females to treat autoimmune diseases, Voskuhl said. Going forward, when one considers sex as a biologic variable in diseases, it can lead to new treatment strategies.

More work is needed to determine whether the same is seen in humans as mice and whether the methylation differences lead to measurable differences in autoimmune disease risk. Voskuhl said the new research is an important step toward better understanding sex differences in disease, a goal that the National Institutes of Health underscored the importance of in 2016 when it mandated that researchers consider sex as a biological variable in their grant applications.

The first authors of the study are graduate student Lisa Golden and associate researcher Yuichiro Itoh, both of UCLA.

Study funders include the National Institutes of Health, the Conrad N. Hilton Foundation, the Tom Sherak MS Hope Foundation and the Rhoda Goetz Foundation for Multiple Sclerosis.

SEE ORIGINAL STUDY

See the original post here:
Father's X chromosome may yield clues to higher rates of autoimmune disease in women - Newswise

Read More...

Rheos Medicines Announces Publication of Perspective in Cell Metabolism Highlighting the Rationale and Potential of Employing Principles of…

December 12th, 2019 4:54 pm

The new field of immunometabolism is the study of how metabolic pathways control immune cell differentiation and function

Rheos Medicines, a biopharmaceutical company harnessing insights in immunometabolism to create a new class of therapeutics for patients with severe autoimmune disorders, inflammatory diseases and cancer, today announced the online publication of a perspective in Cell Metabolism that highlights the rationale and potential of employing principles of immunometabolism to discover and develop novel medicines. The article, entitled The Untapped Opportunity and Challenge of Immunometabolism: A New Paradigm for Drug Discovery, was published online today in Cell Metabolism (DOI: 10.1016/j.cmet.2019.11.014).

Immune cells modulate their energy requirements in response to changes in their environment, which include interactions with pathogens, tumor cells, other immune system cells and molecules such as growth factors and antibodies. The metabolic programs that are induced or inhibited as immune cells respond to such stimuli can drive immune cell activation, differentiation, or suppression. Understanding the mechanisms through which metabolism can dictate the function or fate of immune cells is a new platform for target and biomarker discovery with a goal of identifying new medicines with potential to selectively tune the immune system to amplify or dampen its response. The perspective reviewed the underlying biology of immunometabolism and the new tools to discover and develop novel therapeutics based on this paradigm.

"To exploit this new field of immunometabolism, we have developed and industrialized a platform that comprehensively elucidates the metabolic pathways and targets with potential to control immune cell fate or function, as well as their associated metabolite biomarkers," said Laurence Turka, M.D., Chief Scientific Officer and co-founder of Rheos. "Our approach employs a proprietary integration of metabolomic, transcriptomic, and other data to generate immunometabolism network maps (imMAPs) that characterize immune cell activation and differentiation through a metabolic lens. Our imMAPs have potential to tap currently undiscovered or poorly understood biology and enable development of new therapeutics for a wide range of diseases including autoimmunity and cancer."

Barbara Fox, Ph.D., Chief Executive Officer of Rheos, added, "Immunometabolism has the potential to be the next frontier in drug discovery. Our pioneering product engine has the breadth and power to identify novel metabolic targets across a diverse set of pathways, better understand the metabolic impact of existing therapies and bring the benefits of personalized medicine to autoimmunity. Based on our work to-date, we have initiated drug discovery efforts in a number of programs and we look forward to providing further updates as we continue to make progress."

About Rheos Medicines

Rheos Medicines is a biopharmaceutical company harnessing insights in immunometabolism to develop novel therapeutics for patients with severe autoimmune disorders, inflammatory diseases and cancer. Our approach targets the underlying intracellular metabolism of immune cells and has the potential to unlock a new frontier in drug discovery for immune-mediated disease. Through a proprietary platform and product engine that integrates multiple "omic" datasets, we systematically define the biologic links between immune cell metabolism and function and simultaneously identify new drug targets and biomarkers of disease to bring precision to the treatment of immune-mediated diseases. We have assembled leading scientists whose discoveries opened the field of immunometabolism, clinicians with a deep understanding of immune-mediated diseases, and an experienced biotech leadership team. Rheos was founded by Third Rock Ventures and is located in Cambridge, MA. For more information, please visit http://www.rheosrx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191212005550/en/

Contacts

INVESTORS & MEDIA: Investors: Gad SofferChief Operating Officergsoffer@rheosrx.com 650-477-8183

John Grimaldi, Burns McClellanjgrimaldi@burnsmc.com 212-213-0006 x362

Media: Ryo Imai / Robert Flamm, Ph.D., Burns McClellanrimai@burnsmc.com / rflamm@burnsmc.com 212-213-0006 x315 / 364

Read the original here:
Rheos Medicines Announces Publication of Perspective in Cell Metabolism Highlighting the Rationale and Potential of Employing Principles of...

Read More...

BioAegis Therapeutics Announces Publication: "Delayed Administration of Recombinant Plasma Gelsolin Improves Survival in a Murine Model of Severe…

December 12th, 2019 4:54 pm

MORRISTOWN, N.J., Dec. 12, 2019 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, Inc., a clinical stage company developing technology to address injurious inflammation while protecting immune function and vital organs in diseases driven by inflammation and infection, announces publication of new research findings with recombinant human plasma gelsolin in influenza. The research demonstrates that recombinant human plasma gelsolin therapy dramatically improves survival in a highly lethal influenza animal model.

Access Publication https://f1000research.com/articles/8-1860/v1

Findings Indicate That Plasma Gelsolin Supplementation Can Improve Influenza Outcomes

Seasonal influenza continues to be a cause of substantial morbidity and mortality. The US Center for Disease Control and Prevention (CDC) documented that seasonal influenza was responsible for close to 57,000 deaths during the 2018-2019 season. There is also concern that new strains could cause high death rates similar to past pandemics.

Studies conducted in collaboration with investigators at the Harvard T.H. Chan School of Public Health demonstrated clinical improvement in mice infected with lethal doses of influenza when administering gelsolin after a clinically relevant delay. The current FDA-approved antivirals target the flu virus, but do not address the severe later stage morbidity and mortality that that are the focus of plasma gelsolin (rhu-pGSN) therapy. Currently, resistance is also developing against the antivirals, which is why host-directed therapies are increasingly being sought for development.

Susan Levinson, PhD, Chief Executive Officer of BioAegis Therapeutics stated, Weve previously studied plasma gelsolin against multiple types of drug-sensitive and drug-resistant bacteria and this new data has demonstrated efficacy in influenza, a key viral pandemic threat. Each time we extend our studies with plasma gelsolin, we become even more persuaded of its potential to address serious medical needs where current therapy fails.

Research Presented at Recent Government Influenza Thought Leader Conference

Last month BioAegis was invited to participate in a workshop on REducing Pathogens After Influenza immune Response (repAIR) organized by the US Department of Health and Human Services BARDA (Biomedical Advanced Research and Development Authority), NIH (National Institute of Health) and ASPR (Assistant Secretary for Preparedness and Response). The conferences mission was to, Bring together thought leaders from multiple disciplines in medical research and clinical sciences who are interested in the study of host-based therapeutic interventions to provide more effective treatment of patients hospitalized with severe influenza.

Need for Host-directed Therapeutics Sought by Department of Health and Human Services

According to the Department of Health and Human Services, In the event of an influenza pandemic, or the annual seasonal epidemic, a therapeutic approved to treat individuals with late stage influenza disease could save tens to hundreds of thousands of lives. In addition, there is potential broad applicability of a host-based treatment to other infectious diseases.

Mark Dinubile, MD, Chief Medical Officer of BioAegis Therapeutics presented Plasma Gelsolin As Immunotherapeutic in Pneumonia including studies conducted by BioAegis Chief Scientific Advisor, Dr. Lester Kobzik at the Harvard TH Chan School of Public Health. The presentation highlighted the key finding -- plasma gelsolins unique ability to treat both viral and bacterial infections a pathogen agnostic approach.

While in Washington, D.C., Dr. Susan Levinson, CEO of BioAegis also presented this data at BARDAs TechWatch. BARDA has invested in many infectious threat programs, however, the space where pGSN is effective represents a gap in their portfolio.

About BioAegis Therapeutics

BioAegis Therapeutics Inc. is a clinical stage, private company whose mission is to exploit a key component of the bodys innate immune system to prevent adverse outcomes of diseases driven by inflammation and infection. BioAegis platform of opportunities exploits the multifunctional role of plasma gelsolin, a highly conserved, endogenous human protein.

Gelsolin has the potential to fill a major gap in the current treatment of inflammatory disease by controlling excess inflammation without suppressing the immune response to threats. In addition, recent findings demonstrate gelsolins unique pathogen agnostic approach its ability to treat both viral and bacterial infections.

In 2019, BioAegis successfully completed a Phase 1b/2a Community-Acquired Pneumonia clinical trial. BioAegis now is fundraising for its phase 2b trial in severe pneumonia. This study is designed to demonstrate gelsolin repletion reduces morbidity and mortality in severe pneumonia patients, a group that is at high risk for poor outcomes due to injurious inflammation.

This press release contains express or implied forward-looking statements, which are based on current expectations of management. These statements relate to, among other things, our expectations regarding managements plans, objectives, and strategies. These statements are neither promises nor guarantees but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. BioAegis assumes no obligation to update any forward-looking statements appearing in this press release in the event of changing circumstances or otherwise, and such statements are current only as of the date they are made.

For further information:

Steven Cordovano, 203-952-6373Email: scordovano@bioaegistx.comwww.bioaegistx.com

Visit link:
BioAegis Therapeutics Announces Publication: "Delayed Administration of Recombinant Plasma Gelsolin Improves Survival in a Murine Model of Severe...

Read More...

Depletion of microbiome-derived molecules in the host using Clostridium genetics – Science Magazine

December 12th, 2019 4:54 pm

Chun-Jun Guo

Department of Bioengineering and ChEM-H, Stanford University, Stanford, CA 94305, USA.Jill Roberts Institute for Research in Inflammatory Bowel Disease, Department of Medicine, Weill Cornell Medicine, NY 10021, USA.

Breanna M. Allen

Graduate Program in Biomedical Sciences, Departments of Otolaryngology and Microbiology and Immunology, Helen Diller Family Comprehensive Cancer Center, Parker Institute for Cancer Immunotherapy, University of California, San Francisco, San Francisco, CA 94143, USA.Chan Zuckerberg Biohub, San Francisco, CA 94158, USA.

Kamir J. Hiam

Graduate Program in Biomedical Sciences, Departments of Otolaryngology and Microbiology and Immunology, Helen Diller Family Comprehensive Cancer Center, Parker Institute for Cancer Immunotherapy, University of California, San Francisco, San Francisco, CA 94143, USA.Chan Zuckerberg Biohub, San Francisco, CA 94158, USA.

Dylan Dodd

Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA.Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA 94305, USA.

Will Van Treuren

Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA 94305, USA.Chan Zuckerberg Biohub, San Francisco, CA 94158, USA.

Steven Higginbottom

Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA 94305, USA.Chan Zuckerberg Biohub, San Francisco, CA 94158, USA.

Kazuki Nagashima

Department of Bioengineering and ChEM-H, Stanford University, Stanford, CA 94305, USA.

Curt R. Fischer

Department of Bioengineering and ChEM-H, Stanford University, Stanford, CA 94305, USA.Chan Zuckerberg Biohub, San Francisco, CA 94158, USA.

Justin L. Sonnenburg

Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA 94305, USA.Chan Zuckerberg Biohub, San Francisco, CA 94158, USA.

Matthew H. Spitzer

Graduate Program in Biomedical Sciences, Departments of Otolaryngology and Microbiology and Immunology, Helen Diller Family Comprehensive Cancer Center, Parker Institute for Cancer Immunotherapy, University of California, San Francisco, San Francisco, CA 94143, USA.Chan Zuckerberg Biohub, San Francisco, CA 94158, USA.

Michael A. Fischbach

Department of Bioengineering and ChEM-H, Stanford University, Stanford, CA 94305, USA.Chan Zuckerberg Biohub, San Francisco, CA 94158, USA.

See the article here:
Depletion of microbiome-derived molecules in the host using Clostridium genetics - Science Magazine

Read More...

Using droplet digital PCR to monitor the safety of CAR T cells – Drug Target Review

December 12th, 2019 4:54 pm

CAR T-cell therapy has caused quite a stir in the immunotherapy world, but it is a process that requires precision and care. Quantitative polymerase chain reaction (qPCR) has thus far been the stalwart technique for providing a check on copy numbers, but here Ping Jin explains why droplet digital PCR (ddPCR) is more than a match for this technique.

CHIMERIC antigen receptor (CAR) T cells, first tested in cancer patients less than a decade ago,1 represent the latest generation of adoptive cell therapy and the most personalised approach to date. CAR T-cell therapy is a method of supercharging a patients immune system to fight their cancer and it involves three stages. First, T cells are isolated from a patients blood; then, using either viral vectors, transposon systems or mRNA transduction,2 T cells are genetically modified to express the CAR protein on their surface. Finally, the T cells are amplified in culture and infused back into the patient where they attack the cancer cells.

CAR T-cell therapy is rapidly gaining popularity as a specific method for treating cancer. According to clinicaltrials.gov, there are currently over 300 active or recruiting CAR T-cell therapy trials underway,3 mostly taking place in the US and China.4 According to one forecast, the global market for CAR T-cell therapies is expected to grow to $8 billion by 2028.5 However, since CAR T cells are a living therapy, as opposed to a synthetic drug, the process of preparing them to assure safety and effectiveness in patients is complex.

See the original post here:
Using droplet digital PCR to monitor the safety of CAR T cells - Drug Target Review

Read More...

Trending News: Hypothyroidism Linked to Increased All-Cause Mortality in Patients 60 Years or Older – Pharmacy Times

December 12th, 2019 4:54 pm

Trending News: Hypothyroidism Linked to Increased All-Cause Mortality in Patients 60 Years or Older

Two migraine prevention agents, cinnarizine and sodium valproate, were shown to be safe and effective in reducing incidence and severity of migraine within children and adolescents, according to the American Journal of Managed Care. In a randomized double-blind placebo-controlled trial including 149 Iranian pediatric and adolescent patients, patients were randomly assigned at 1:1:1 ratio to receive cinnarizine, sodium valproate, or placebo. Compared with placebo, the 2 preventive agents exhibited significant reductions in migraine incidence and severity, warranting further analyses into their efficacy among the global population.

New research indicates that hypothyroidism could be linked to increased all-cause mortality in patients aged 60 years and older, according to MD Magazine. An international team of researchers conducted a systematic review and meta-analysis of PubMed, Embase, Cochrane Library, Scopus, and Web of Science databases. Their findings indicate that patients aged 60 years or older with subclinical hypothyroidism (those who have a milder thyroid dysfunction) may not benefit from a treatment with synthetic thyroid hormone.

Read more from the original source:
Trending News: Hypothyroidism Linked to Increased All-Cause Mortality in Patients 60 Years or Older - Pharmacy Times

Read More...

Aspen Neuroscience Launches With $6.5 Million Seed Funding to Advance First-of-its-Kind Personalized Cell Therapy for Parkinson’s Disease – P&T…

December 12th, 2019 4:53 pm

SAN DIEGO, Dec. 12, 2019 /PRNewswire/ -- Aspen Neuroscience, Inc. today announced its launch following a $6.5 million seed round led by Domain Associates and Axon Ventures and including Alexandria Venture Investments,Arch Venture Partners,OrbiMedand Section 32 to develop the first autologous cell therapies for Parkinson's disease. Aspen's proprietary approach was developed by the company's co-founders, Jeanne F. Loring, Ph.D., Professor Emeritus and founding director of the Center for Regenerative Medicine at The Scripps Research Institute, and Andres Bratt-Leal, Ph.D., a former post-doctoral researcher in Dr. Loring's lab. The company was initially supported by Summit for Stem Cell, a founding partner and non-profit organization which provides a variety of services for people with Parkinson's disease. Aspen is led by industry veteran Howard J. Federoff, M.D., Ph.D., as Chief Executive Officer.

Parkinson's disease is characterized by the loss of specific brain cells that make the chemical dopamine. Without dopamine, nerve cells cannot communicate with muscles and people are left with debilitating motor problems. Aspen is focusing on human pluripotent stem cells, cultured cells that can become any cell type in the human body. The company's research is specific to induced pluripotent stem cells (iPSCs), which it develops by taking a skin biopsy from a person with Parkinson's disease and turning the tissue into pluripotent stem cells using genetic engineering. Aspen then differentiates the pluripotent stem cells into dopamine-releasing neurons that can be transplanted into that same person (autologous), thereby restoring the types of neurons lost in Parkinson's disease.

As an autologous cell therapy for Parkinson's disease, Aspen's treatment would eliminate the need for immunosuppression because the neurons are transplanted back into the same patient from which they were generated. The use of immunosuppression is necessary with currently available cell therapies for Parkinson's disease and when transplanting cells from one patient to another (allogeneic) to prevent rejection but can pre-dispose the patient to life-threatening complications including infection and add cost to the patient and health system. Aspen is the only company in the world offering an autologous neuron replacement therapy for Parkinson's disease.

Aspen encompasses a powerful executive leadership team including Dr. Federoff who, in addition to his leadership roles at the UC Irvine Health System, was the Executive Vice President for Health Sciences and the Executive Dean of Medicine at Georgetown University. Dr. Federoff also has significant biotech industry experience including co-founding MedGenesis Therapeutix and Brain Neurotherapy Bio, as well as leading the U.S. Parkinson's Disease Gene Therapy Study Group. The company is also proud to announce the addition of several experienced and well-known members to its leadership team including Edward Wirth, M.D., Ph.D., as Chief Medical Officer.

Dr. Wirth currently serves as the Chief Medical Ofcer for Lineage Cell Therapeutics where he oversees clinical development of its two therapeutic programs for spinal cord injuries and lung cancer. He received his M.D. and Ph.D. from the University of Florida in 1994 and remained to conduct postdoctoral research including leading the University of Florida team that performed the rst human embryonic spinal cord transplant in the U.S. Dr. Wirth went on to serve as the Medical Director for Regenerative Medicine at Geron Corporation where the world's rst clinical trial of human embryonic stem cell (hESC)-derived product occurred which demonstrated initial clinical safety.

Drs. Federoff and Wirth are joined by Dr. Loring, as Chief Scientific Officer; Jay Sial, as Chief Financial Officer; Andres Bratt-Leal, Ph.D., as Vice President of Research and Development; Thorsten Gorba, Ph.D., as Senior Director of Manufacturing and Naveen M. Krishnan, M.D., M.Phil., as Senior Director of Corporate Development.

"Aspen is developing a restorative, disease modifying autologous neuron therapy for people suffering from Parkinson's disease," said Dr. Federoff. "We are fortunate to have such a high-caliber scientific and medical leadership team to make our treatments a reality. Our cell replacement therapy, which originated in the laboratory of Dr. Jeanne Loring and was later supported by Summit for Stem Cell and its President, Ms. Jenifer Raub, has the potential to release dopamine and reconstruct neural networks where no disease-modifying therapies exist."

Aspen's lead product (ANPD001) is currently undergoing investigational new drug (IND)-enabling studies for the treatment of sporadic Parkinson's disease. Aspen is also developing a gene-edited autologous neuron therapy (ANPD002) that is in the research stage and targeted toward familial forms of Parkinson's disease beginning with the most common genetic variant in the gene encoding glucocerebrosidase (GBA). Aspen leverages proprietary machine-learning tools and artificial intelligence to ensure quality control during manufacturing and to deliver a safe and reproducible product for each cell line.

"Aspen's financial backing, combined with its experienced and proven leadership team, positions it well for future success," said Kim P. Kamdar, Ph.D., Partner at Domain Associates, one of Aspen's seed investors. "Domain prides itself on investing in companies that can translate scientific research into innovative medicines and therapies that make a difference in people's lives. We clearly see Aspen as fitting into that category, as it is the only company using a patient's own cells for replacement therapy in Parkinson's disease."

About Aspen Neuroscience

Aspen Neuroscience Inc. is a development stage, private biotechnology company that uses innovative genomic approaches combined with stem cell biology to deliver patient-specific, restorative cell therapies that modify the course of Parkinson's disease. Aspen's therapies are based upon the scientific work of world-renowned stem cell scientist, Dr. Jeanne Loring, who has developed a novel method for autologous neuron replacement. For more information and important updates, please visithttp://www.aspenneuroscience.com.

View original content to download multimedia:http://www.prnewswire.com/news-releases/aspen-neuroscience-launches-with-6-5-million-seed-funding-to-advance-first-of-its-kind-personalized-cell-therapy-for-parkinsons-disease-300973830.html

SOURCE Aspen Neuroscience

More:
Aspen Neuroscience Launches With $6.5 Million Seed Funding to Advance First-of-its-Kind Personalized Cell Therapy for Parkinson's Disease - P&T...

Read More...

New Mechanism of Bone Maintenance and Repair Discovered – Technology Networks

December 12th, 2019 4:53 pm

Led by researchers at Baylor College of Medicine, a study published in the journal Cell Stem Cell reveals a new mechanism that contributes to adult bone maintenance and repair and opens the possibility of developing therapeutic strategies for improving bone healing.

Adult bone repair relies on the activation of bone stem cells, which still remain poorly characterized, said corresponding author Dr. Dongsu Park, assistant professor of molecular and human genetics and of pathology and immunology at Baylor. Bone stem cells have been found both in the bone marrow inside the bone and also in the periosteum the outer layer of tissue that envelopes the bone. Previous studies have shown that these two populations of stem cells, although they share many characteristics, also have unique functions and specific regulatory mechanisms.

Of the two, periosteum stem cells are the least understood. It is known that they comprise a heterogeneous population of cells that can contribute to bone thickness, shaping and fracture repair, but scientists had not been able to distinguish between different subtypes of bone stem cells to study how their different functions are regulated.

In the current study, Park and his colleagues developed a method to identify different subpopulations of periosteum stem cells, define their contribution to bone fracture repair in live mouse models and identify specific factors that regulate their migration and proliferation under physiological conditions.

Periosteal stem cells are major contributors to bone healing

The researchers discovered specific markers for periosteum stem cells in mouse models. The markers identified a distinct subset of stem cells that contributes to life-long adult bone regeneration.

We also found that periosteum stem cells respond to mechanical injury by engaging in bone healing, Park said. They are important for healing bone fractures in the adult mice and, interestingly, their contribution to bone regeneration is higher than that of bone marrow stem cells.

In addition, the researchers found that periosteal stem cells also respond to inflammatory molecules called chemokines, which are usually produced during bone injury. In particular, they responded to chemokine CCL5.

Periosteal stem cells have receptors molecules on their cell surface that bind to CCL5, which sends a signal to the cells to migrate toward the injured bone and repair it. Deleting the CCL5 gene in mouse models resulted in marked defects in bone repair or delayed healing. When the researchers supplied CCL5 to CCL5-deficient mice, bone healing was accelerated.

The findings suggested potential therapeutic applications. For instance, in individuals with diabetes or osteoporosis in which bone healing is slow and may lead to other complications resulting from limited mobility, accelerating bone healing may reduce hospital stay and improve prognosis.

Our findings contribute to a better understanding of how adult bones heal. We think this is one of the first studies to show that bone stem cells are heterogeneous and that different subtypes have unique properties regulated by specific mechanisms, Park said. We have identified markers that enable us to tell bone stem cell subtypes apart and studied what each subtype contributes to bone health. Understanding how bone stem cell functions are regulated offers the possibility to develop novel therapeutic strategies to treat adult bone injuries.

Reference

Ortinau et al. (2019) Identification of Functionally Distinct Mx1+SMA+ Periosteal Skeletal Stem Cells. Cell Stem Cell. DOI: https://doi.org/10.1016/j.stem.2019.11.003

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Continued here:
New Mechanism of Bone Maintenance and Repair Discovered - Technology Networks

Read More...

LentiGlobin Gene Therapy Continues to Show Promising Results in SCD, Updated Trial Data Shows – Sickle Cell Anemia News

December 12th, 2019 4:53 pm

LentiGlobin, Bluebird Bios investigational gene therapy for sickle cell disease (SCD), continues to show promising results in SCD patients participating in the companys Phase 1/2 HGB-206 clinical trial, according to the latest study data.

The new findings which included data from additional patients treated in the trial, updated data from those previously reported, and exploratory analyses were presented at the 61st American Society of Hematology (ASH) Annual Meeting and Exposition, held Dec. 6-10 in Orlando, Fla.

LentiGlobinisa gene therapy that has been developed to increase the levels of hemoglobin the protein that transports oxygen in the blood in people with SCD.

The therapy works by delivering functional copies of a modified form of the beta-globin gene (A-T87Q-globin gene) into patients red blood cell precursors, known as hematopoietic stem cells, or HSCs. Once these precursors differentiate, their red blood cells start producing a modified version of hemoglobin, called HbAT87Q.

By boosting the production of this anti-sickling form of the protein, LentiGlobin reduces the proportion of defective hemoglobin in patients red blood cells. That, in turn, reduces the sickling and destruction of these red blood cells and other complications associated with SCD.

The safety and efficacy of LentiGlobin is currently being evaluated in three groups identified as A-C of SCD patients participating in Bluebirds ongoing open-label, Phase 1/2 HGB-206 trial (NCT02140554).

Those in group A were treated per the original trial protocol. Meanwhile, those in groups B and C received an enhanced treatment protocol, approved in 2016, that is designed to increase the therapys efficiency. In groups A and B, patients HSCs were extracted from the bone marrow, while in group C, they were extracted from the blood.

As of the data cutoff date of August 26, 2019, seven participants in group A, two in group B, and 17 in group C had been treated with LentiGlobin. According to new data presented at the meeting, only two patients from group A required regular blood transfusions after the treatment.

In addition, the updated findings revealed that the levels of anti-sickling HbAT87Q remained stable in all participants from groups A and B over a post-treatment follow-up period of three years. Similarly, levels of total hemoglobin also were found to have remained stable in both patient groups over a two-year follow-up.

At the trial participants last visit, the median levels of anti-sickling HbAT87Q were 0.9 g/dL among those from group A, and 3.6 g/dL and 7.1 g/dL in the two patients from group B. The median levels of total hemoglobin were 9.0 g/dL among patients from group A, and 11.3 g/dL and 13.0 g/dL among those from group B.

Normal levels of hemoglobin in the blood range from 12.5 to 17.5 g/dL.

Among 12 patients from group C who were followed for at least six months, the median levels of anti-sickling HbAT87Q made up at least 40% of their total hemoglobin. At their last visit, the levels of anti-sickling HbAT87Q ranged from 2.7 to 9.0 g/dL, and the levels of total hemoglobin from 9.3 to 15.2 g/dL.

In groups A and B, LentiGlobin reduced the frequency of painful vaso-occlusive crises (VOCs) and acute chest syndrome (ACS) in the two years following treatment.

Nine patients from group C who were followed for at least six months had experienced four or more VOCs or ACS episodes in the two years prior to receiving LentiGlobin. Treatment with the gene therapy led to a reduction of 99% in the frequency of annual VOCs and ACS. In this group, there were no reports of ACS or severe VOCs for up to 21 months following treatment.

Moreover, among those from group C, LentiGlobin reduced the levels of different markers of red blood cells destruction, including reticulocytes, lactate dehydrogenase (LDH), and bilirubin.

LentiGlobins safety profile was consistent with previous data. No serious adverse events related to treatment were reported during the study. Only one mild, non-serious event of hot flush was found to be related to LentiGlobin. That event was rapidly resolved and did not require treatment.

Exploratory analyses were performed in a sub-group of patients from all three groups. In 12 participants who had been followed for at least six months, more than 70% of the individuals red blood cells were found to contain the anti-sickling HbAT87Q at the last study visit, these analyses showed. Moreover, in four of these patients, nearly all their red blood cells (90%) were positive for HbAT87Q.

In addition, exploratory analyses revealed that participants red blood cells were less prone to sickling following treatment with LentiGlobin.

At ASH, the growing body of data from our clinical studies of LentiGlobin for SCD reflects results from 26 treated patients with up to four years of follow-up, David Davidson, MD, Bluebird Bios chief medical officer, said in a press release.

We continue to observe patients treated in Group C producing high levels of gene-therapy derived anti-sickling hemoglobin, HbAT87Q, accounting for at least 40% of total hemoglobin in those with six or more months of follow-up, and exploratory assays show that HbAT87Q is present in most red blood cells of treated patients, Davidson said.

The robust production of HbAT87Q was associated with substantial reductions of sickle hemoglobin, HbS, as well as improvement in key markers of hemolysis [red blood cells destruction]. Most importantly, patients in Group C have not experienced any episodes of acute chest syndrome or serious vaso-occlusive crises following LentiGlobin for SCD treatment, he added.

The company is recruiting participants with transfusion-dependent -thalassemia (TDT) for a Phase 3 trial (NCT03207009) testing LentiGlobin. Moreover, according to the companys pipeline, there is a Phase 2/3 trial planned in sickle cell disease for this gene therapy.

Joana is currently completing her PhD in Biomedicine and Clinical Research at Universidade de Lisboa. She also holds a BSc in Biology and an MSc in Evolutionary and Developmental Biology from Universidade de Lisboa. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells cells that make up the lining of blood vessels found in the umbilical cord of newborns.

Total Posts: 94

Margarida graduated with a BS in Health Sciences from the University of Lisbon and a MSc in Biotechnology from Instituto Superior Tcnico (IST-UL). She worked as a molecular biologist research associate at a Cambridge UK-based biotech company that discovers and develops therapeutic, fully human monoclonal antibodies.

More:
LentiGlobin Gene Therapy Continues to Show Promising Results in SCD, Updated Trial Data Shows - Sickle Cell Anemia News

Read More...

Global Stem Cell Therapy Market 2019-2025 Analyzed by Business Growth, Development Factors, Applications, and Future Prospects – Technology Magazine

December 12th, 2019 4:53 pm

Autologous stem cell therapy market segment is anticipated to witness around 10% growth throughout the forecast timeframe. Autologous stem cell therapy has high compatibility with patients immune system and showcases strong efficacy. Additionally, it eliminates the need for finding donor and reduces the overall cost of treatment. Aforementioned advantages offered by autologous stem cell therapy will augment its demand thereby, escalating segment growth.

Oncology segment held over 37% revenue in 2018. Increasing prevalence of cancer globally will increase the demand for advanced stem cell Therapy. Metastatic cancer cells are difficult to destroy utilizing conventional methods. Radiations and chemotherapy cannot eradicate the disease completely and also results in several complications. Stem cells have unique properties such as secretion of bioactive factors and migration towards cancer cells promotes tumor targeting that are proven to be effective in treatment of cancer. Aforementioned factors will escalate the segmental growth.Rising government initiatives for promoting stem cell therapy in developed as well as developing countries will propel industry growth. Increasing government spending on research activities aimed at development of stem cell therapy for treatment of life-threatening diseases such as cancer. The government ensures that laboratories, research and academic centers are well-equipped with necessary equipment and advanced devices for facilitating the stem cell therapy research processes. Aforementioned factors are expected to boost the stem cell therapy market growth.

Get a Sample Copy of this [emailprotected]https://www.gminsights.com/request-sample/detail/3331

Increasing efforts undertaken by companies for improving efficacy of stem cell therapy will fuel industry growth. Stem cells possess totipotency that enables them to transform into any differentiated cell. Stem cells play pivotal role in treatment of chronic diseases such as cancer, cardiovascular diseases and degenerative disorders. 0Currently, hematopoietic, embryonic and mesenchymal cells are being researched as they have the ability to cure several complications. Companies commercialize these stem cell products for providing effective therapy that should prove beneficial for the industry growth. However, ethical issues associated with stem cell therapy may affect industry growth to some extent.

Hospitals segment was valued around USD 4 billion in 2018. Significant growth is attributed to increasing prevalence of chronic diseases. Annually, large number of patients prefer stem cell therapy offered at hospitals as a treatment option to avoid complications caused due to invasive methods. Hospitals have dedicated resources allocated for providing uncompromised care to patients that speeds up the recovery process. Moreover, hospitals affiliated with government authorities receives enough funding and have the ability to provide superior quality stem cell therapy. Above mentioned factors will augment patients preference towards hospitals that will exceed segment growth.

Make an inquiry for purchasing this report @https://www.gminsights.com/inquiry-before-buying/3331

Asia Pacific stem cell therapy market held around 20% revenue in 2018. Substantial revenue share can be attributed to the increasing awareness regarding availability of stem cell therapies. Moreover, government encourages scientists and researchers to carry out studies and thesis on stem cell therapies in order to develop innovative solutions for treating chronic diseases. Also, several developing countries in the region have witnessed industry growth opportunities as government provide funds to establish stem cell centers. For instance, in Singapore JTC Corporation has established Biopolis, that is a biomedical research center of stem cell science. Such government initiatives in Asian countries will positively impact regional market growth.

More Insightful [emailprotected] https://www.marketwatch.com/press-release/15bn-by-2025-stem-cell-therapy-market-2019-set-for-massive-growth-2019-07-22

Prominent industry players operational in stem cell therapy market are Astellas Pharma Inc, Cellectis, Celyad, Novadip Biosciences, Gamida Cell, Capricor Therapeutics, Cellular Dynamics, CESCA Therapeutics, DiscGenics, OxStem, Mesoblast Ltd, ReNeuron Group and Takeda Pharmaceuticals. Industry players implement various strategies such as collaboration, acquisition, merger, product launch to sustain in the market. For instance, in February 2018, Astellas acquired Universal Cells so that they can utilize proprietary technology to manufacture pluripotent stem cells. This strategy will help Astellas to develop innovative solutions that will provide competitive advantage to company.

Related Reports:

Vaccines Market: https://www.marketwatch.com/press-release/global-vaccines-market-size-2019-outlook-opportunity-and-demand-analysis-report-by-2025-2019-09-12

Patient Handling Equipment Market: https://www.marketwatch.com/press-release/patient-handling-equipment-market-size-2019-outlook-opportunity-and-demand-analysis-report-by-2025-2019-09-12

About Global Market Insights:

Global Market Insights, Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider; offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with penetrative insights and actionable market data specially designed and presented to aid strategic decision making. These exhaustive reports are designed via a proprietary research methodology and are available for key industries such as chemicals, advanced materials, technology, renewable energy and biotechnology.

Contact Us:

Arun Hegde

Corporate Sales, USA

Global Market Insights, Inc.

Phone:1-302-846-7766

Toll Free: 1-888-689-0688

Email: [emailprotected]

Read more:
Global Stem Cell Therapy Market 2019-2025 Analyzed by Business Growth, Development Factors, Applications, and Future Prospects - Technology Magazine

Read More...

How Far Are We from (Accurately and Safely) Editing Human Embryos? – Singularity Hub

December 12th, 2019 4:53 pm

We can already edit genes in human embryos. We can even do it in a way to pass the edits down generations, fundamentally changing a familys genetic makeup.

Doing it well, however, is far more difficult.

Its impossible to talk about human germline genome editing without bringing up the CRISPR baby fiasco. Over a year ago, a rogue Chinese scientist performed an edit on fertilized human embryos that, in theory, makes them resistant to HIV infection. Two twin girls were born, and both had multiple unplanned edits in their genome with unknown health consequencesconsequences that may be passed on to their offspring.

The brash attempt at making scientific history clearly shows that, ethics and morality issues aside, when it comes to germline editingthat is, performing gene edits in egg, sperm, or the embryowere simply technologically not there. Make no mistake: CRISPR may one day wipe out devastating genetic diseases throughout entire family lines, or even the human race. But to harness its power responsibly, there are plenty of technical challenges we need to master first.

This week, Rebecca Lea and Dr. Kathy Niakan at the Human Embryo and Stem Cell Laboratory at the Francis Crick Institute in London, UK, laid out those challenges in a sweeping articlein Nature. CRISPR as a gene editor is getting more specific and efficient by the day, they explained. However, for it to gradually move into germline editing, we also need to understand how the tool tangos with cells during early human development.

The data, they argue, will not only let us zoom into the creation of human life. It will also help inform the debate about potential safe and effective clinical uses of this technology, and truly unlock the doors to the human genome for good.

Correcting dangerous genetic mutations is one reason to pursue germline editing, but CRISPRing human embryos can also unveil insights into the very first stages of human embryo development. Research shows that trying to understand how human embryos form by studying mice might not be the best route, especially when it comes to using those results to tackle infertility and other medical problems. With CRISPR, we have insight into these early stages that were previously completely unattainable. We might only solve infertility issues, but perhaps also allow same-sex couples to have genetic children in the future.

Another argument is that couples already screen for life-threatening mutations during IVF, and using CRISPR on top of that is unnecessary. Not true, the authors argued. When both parents carry a similar mutation that robs them of the ability to have a healthy child, CRISPRnot selection during IVFis the answer. Ultimately, providing more options for patients empowers them to make the choice that is best for their family and circumstances, they said.

This is where it gets complicated.

The big one: were still trying to tease out how CRISPR works in cells that form the embryo, in hopes that we can cut down on potential mistakes.

Let me explain: all cells in the body have a cell cycle, somewhat analogous to a persons life cycle. Many checkpoint life events happen along the way. The cell could decide to divide and have kids, so to speak, or temporarily halt its cycle and stop its own aging. During a cycle, the cells DNA dramatically changes in number and packaging in preparation for its next stage in life.

The problem? The way CRISPR works heavily depends on the cell cycle. Although dubbed an editor, CRISPR actually vandalizes the genome, creating breaks in the DNA strands. What we call gene editing is the cells DNA repair system kicking into high gear, trying to patch up the mess CRISPR left behind. Adult cells that cant be repaired stop their own life cycle at a checkpoint for the greater good. In embryos, however, cells arent nearly as altruistic. Their checkpoints arent fully developed, so they might continue to develop even with severe mutations. Zooming back to the full picture, it means that the resulting early-stage embryo may keep accumulating damage, until it fails in the mothers womb.

To get around this, scientists have tried other ways to push an embryo into accepting a healthy DNA template after a CRISPR snip, which in theory would cut down on unwanted mutations. One idea is injecting the CRISPR machinery at a specific time into fertilized eggs, so it catches the early-stage embryo at just the right time to reduce DNA breaks in both strands. While theoretically possible, the process is kind of like a person trying to jump from a high-speed train into a specific cabin on a rapidly rotating Ferris wheel while blindfolded.

But science is making progress. Although we dont have a detailed movie of cell cycles in human embryos yet, multiple labs are beginning to piece one together, with hopes itll eventually help take off the blindfold when injecting CRISPR. Others are looking into adding CRISPR to sperm before fertilization as an alternative.

At the same time, scientists are also trying to characterize the entire scope of mutations caused by CRISPR. Its not just adding, swapping, or deleting specific letters in genes. Rather, the range of mutations is more complex, including large swaths of genetic rearrangements, unintended cuts relatively far from targeted spots, and other dramatic DNA lesions following CRISPR action. Its perhaps not surprising that the edits in CRISPR babies didnt work as intended.

Base editors, which swap one genetic letter for another, might be a better approach compared to the classic hack-and-paste, the authors said. So far, however, the tools havent yet been validated in embryosnot even those from mice.

Finally, for the edit to make a difference to the child, the embryo has to develop normally inside a womb into a baby. But success rates for assisted reproductive technologies are already fairly low. Add in a dose of genetic editing tool that cuts into an already-sensitive genomic landscape, and it becomes incredibly hard to maintain the health of the edited embryo.

Putting it all together, there is simply not enough data at present to understand the capability of early[embryos] to repair DNA, the authors said.

Far from it. Although theres much we dont yet understand, we do have an impressive range of tools to predict and evaluate mutations in human embryos. Exactly how to determine whether a gene-edited embryo is healthy remains up for debatefor example, is five unexpected mutations considered ok? What about 500 or 5,000?

That said, just having tools to diagnose the genetic health of an embryo from a tiny bit of DNA is already extremely useful, especially if we as a society decide to move into germline editing as a treatment.

With machine learning making an ever-larger splash in computational biology, these predictive tools will only become more accurate. Add to that ever-more-effective CRISPR variations, and were on the right trackas long as any potential applications of embryo editing only come after in-depth public and policy discussions and fit a number of strict ethical and safety criteria, the authors said.

In response to the CRISPR baby scandal, multiple governments and the World Health Organization have all drafted new guidelines or legislation to tap on the brakes. The technology isnt mature enough for clinical use, the authors said, and much more work is needednot just to further improve CRISPR tools, but especially for understanding how it works in human embryos.

Ultimately, were talking about potentially engineering the future of the human race. Tiptoeing, rather than stumbling ahead, is the least we can do. One must ensure that the outcome will be the birth of healthy, disease-free children, without any potential long-term complications, the authors concluded.

Image Credit: Image by marian anbu juwan from Pixabay

View post:
How Far Are We from (Accurately and Safely) Editing Human Embryos? - Singularity Hub

Read More...

Strategic Plan To Cure Hepatitis B in the Making – Technology Networks

December 12th, 2019 4:53 pm

A highly effective vaccine to prevent hepatitis B virus (HBV) infection has been available for nearly 40 years, yet millions of people worldwide continue to become infected with the liver-attacking virus and more than 600,000 die from its complications each year, according to the U.S. Centers for Disease Control and Prevention. A new strategic plan from the National Institutes of Health outlines efforts to intensify ongoing HBV research with the goals of developing a cure and improving scientific understanding of the virus while creating improved strategies for screening and treating patients.

HBV is transmitted through sex, contact with infected blood or bodily fluids, or from an infected mother to her baby, and can result in either an acute infection that resolves or a chronic infection. Chronic HBV infection can lead to serious health issues including cirrhosis (scarring of the liver), liver failure or liver cancer. Approximately 80% to 90% of infants infected during the first year of life will develop chronic infection, while only 5% of people infected as adults will become chronically infected. Between 850,000 and 2 million people in the United States have chronic hepatitis B; globally, that number is 257 million, according to the World Health Organization.

Although treatments are available to control HBV infection, they must be taken for years if not for life. Additionally, high medication costs, the need for continuous disease monitoring and adhering to treatment regimens present significant burdens for people with chronic hepatitis B. Even among those treated for chronic hepatitis B, the risk of developing cirrhosis and liver cancer remains elevated.

Scientific discoveries within the past decade suggest that a hepatitis B cure is possible. The new NIH plan defines a hepatitis B cure as a sustained loss of a specific protein on the surface of HBV called hepatitis B virus surface antigen preferably with antibodies against the antigen and undetectable viral DNA after completion of a finite course of treatment. Ideally, a hepatitis B cure would also reduce a persons risk of liver failure and liver cancer. To effectively address the global public health challenge posed by HBV, a curative treatment will need to complement better approaches to screening, follow-up care, and vaccination coverage.

The Strategic Plan for Trans-NIH Research to Cure Hepatitis B focuses on three key research areas. The first priority calls for a better understanding of hepatitis B biology, including the viral and host factors that lead to disease, immunity, reactivation and transmission, as well as the impact of co-infections with other hepatitis viruses and HIV. An improved understanding of these factors and the HBV lifecycle is essential to developing a cure.

The second priority emphasizes the development and sharing of tools and resources to support fundamental research and product development. This includes standardizing and sharing reagents and assays; improving and creating new animal models to study the progression of human liver disease and mother-to-child transmission; and establishing biomarkers for disease progression and response to therapy.

The third priority calls for the creation of strategies to cure and prevent hepatitis B infection. A cure could include approaches to blocking viral replication, stimulating the anti-HBV immune responses or eliminating HBV-infected cells. However, achieving a cure requires strengthening existing public health efforts for promoting hepatitis screening, ensuring that high-risk and underserved populations have access to vaccination, and prioritizing follow-up to care and adherence to treatment, according to the plan.

The strategic plan builds on NIHs ongoing hepatitis B research portfolio and the U.S. National Viral Hepatitis Action Plan. NIH sought input from academia, patient advocacy organizations, private and nonprofit companies, government organizations, and clinical trial networks funded by the NIH in the development of this strategic plan.

Reference

Ortinau et al. (2019) Identification of Functionally Distinct Mx1+SMA+ Periosteal Skeletal Stem Cells. Cell Stem Cell. DOI: https://doi.org/10.1016/j.stem.2019.11.003

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

See the rest here:
Strategic Plan To Cure Hepatitis B in the Making - Technology Networks

Read More...

Myelodysplastic Syndrome Treatment Market: Research Analysis by Basic Information, Manufacturing Base, Sales Area and Regions – Drnewsindustry

December 12th, 2019 4:53 pm

Myelodysplastic syndrome (MDS) is a blood disorder caused due to the production of abnormal blood cells in bone marrow. Bone marrow failure leads to drop in the number of healthy blood cells in the body. In MDS, bone marrow does not produce healthy red blood cells, white blood cells, and/or platelets. Symptoms of MDS in the beginning are no specific than causes of pancytopenia i.e., deficiency of RBC, WBC and platelets. Therefore, the final diagnosis of MDS is done after examination of the cells of bone marrow.

Report Overview @

http://www.transparencymarketresearch.com/myelodysplastic-syndrome-treatment-market.html

Bone marrow sample is taken from inside of a bone (usually the hip bone) and examined with a microscope using special stains to look for abnormal and immature cells. According to the American Cancer Society, over 13,000 new cases of MDS occur in the U.S. each year. According to the National Organization for Rare Disorders, 30% of patients with MDS can develop a form of blood cancer known as acute myeloid leukemia. Majority of patients diagnosed with MDS are aged between 65 and 70; however, MDS can affect people of any age and the risk of developing MDS increases with age.

The global myelodysplastic syndrome treatment market is driven by rise in the global geriatric population as MDS is most commonly found in this population and remains an incurable disease. Moreover, significant progress has been made in the diagnosis of MDS with the help of sequencing technologies. Chromosomal abnormalities can be identified in MDS patients with these technologies. These are useful for both diagnosis and prognosis in MDS patients. For instance, patients with chromosome 5q deletions are more likely to respond to lenalidomide. No new drugs have been approved for MDS by the U.S. Food and Drug Administration since 2006. Current available therapies can be efficacious, but are generally not curative. Some of the challenges in developing new treatments are the complexity and heterogeneity of MDS as a disease.

Want to know the obstructions to your companys growth in future? Request a PDF sample here

The global myelodysplastic syndrome treatment market can be segmented based on type of treatment and region. In terms of type of treatment, the market can be classified into supportive therapy, growth factors, chemotherapy (including hypomethylating agents), and stem cell transplant. Cytarabine, azacitidine, decitabine, and lenalidomide are the major drugs used during chemotherapy.

Stem cell transplant is the only cure for MDS; however, majority of patients are not treated with stem cell transplant due to various factors such as high treatment cost, transplant-related deaths, and relapse rate at five years (as high as 40%). The chemotherapy segment is expected to hold major share of the global myelodysplastic syndrome treatment market due to larger application and less complications than other therapies such as stem cell transplant.

To Obtain All-Inclusive Information On Forecast Analysis Of Global Market, Request A PDF Brochure Here.

Geographically, the global myelodysplastic syndrome treatment market can be segmented into North America, Europe, Asia Pacific, Latin America, Africa, and Middle East. North America is projected to dominate the global myelodysplastic syndrome market during the forecast period due to factors such as the rise in aging population and growing awareness about the disease among the population coupled with unmet medical needs in this region.

Key players operating in the global myelodysplastic syndrome treatment market are Celgene Corporation, Otsuka Holdings Co., Ltd., Sandoz, Inc., Dr. Reddys Laboratories, Inc., Accord Healthcare Ltd., Mylan N.V., and Pfizer, Inc.

See the article here:
Myelodysplastic Syndrome Treatment Market: Research Analysis by Basic Information, Manufacturing Base, Sales Area and Regions - Drnewsindustry

Read More...

More Bexar County Youth Are Being Diagnosed With Type 2 Diabetes, Prediabetes – Texas Public Radio

December 12th, 2019 4:52 pm

THURSDAY at noon on "The Source" An estimated14%of Bexar County's population lives with Type 2 diabetes. This preventable disease typically presents later in life, but is increasingly contracted by youn peoplewho can experience earlier, more advanced complications such as blindness, amputations and even death.

Of the more than30 millionAmerican adults with diabetes, approximately90%live with Type 2, which is managed with diet, exercise and insulin.Approximately half a million Texans are still undiagnosed.

Risk factors include poor diet, obesity, sedentary lifestyle and prediabetes. Children diagnosed with Type 2 diabetes often have a family history with the disease.

According to the Centers for Disease Control and Prevention, nearly 1 in 5 adolescents are living with prediabetes, defined as having blood sugar levels higher than normal but not yet at the threshold for an official Type 2 diabetes diagnosis.

Is there a public health strategy to combat the epidemic of Type 2 diabetes in Bexar County? Who is most at risk and what's being done to break the cycle?

What are the potential short and long term effects of Type 2 diabetes? Can it be reversed with healthier living? What does responsible treatment entail and how do individuals without health insurance manage?

What is to blame for the rising rates of Type 2 and prediabetes in young people? Could earlier identification and treatment help mitigate the disease?

The Texas Diabetes Institute is recruiting for diabetes-related clinical trials. Interested listeners can call 210-358-7200 for more information.

Guests:

"The Source" is a live call-in program airing Mondays through Thursdays from 12-1 p.m. Leave a message before the program at (210) 615-8982. During the live show, call 210-614-8980, email thesource@tpr.org or tweet @TPRSource.

*Audio for this interview will be available by 3:30 p.m. on Thursday, December 12.

Excerpt from:
More Bexar County Youth Are Being Diagnosed With Type 2 Diabetes, Prediabetes - Texas Public Radio

Read More...

Resolve to take charge of diabetes – The Daily Advocate

December 12th, 2019 4:52 pm

GREENVILLE A new year is a great time to learn how to improve your health by increments with a free six-week Healthy U workshop for adults living with diabetes or pre-diabetes 2-4:30 p.m. on Fridays, January 10 through February 14 at Family Health (Conference Room), 5735 Meeker Road, Greenville. The workshop is open to adults of any age living with diabetes, pre-diabetes, and/or their caregivers.

Workshops need a minimum number of participants in order to take place. Register by calling Jane Urlage at (937) 547-2319, ext. 1229 or emailing jurlage@familyhealthservices.org. Sign up now to celebrate a healthier Valentines Day.

Healthy U is an evidence-based, interactive, small group workshop proven to improve quality of life and reduce health care expenses by increasing self-confidence and providing new skills to better manage symptoms and feel healthier. Participants explore new ways to address challenges common to anyone with diabetes. This workshop is different from clinical diabetes programs, and instead focuses on common problems like chronic pain, nutrition, exercise, medication use, emotions, and communicating with doctors and family. Participants develop skills and coping strategies to manage symptoms through setting achievable goals, problem-solving, decision-making, social support, and more.

Everyone who completes the course receives the companion textbook, Living a Healthy Life with Chronic Conditions, and a relaxation CD.

Workshops are supported by the Area Agency on Aging, PSA 2. The Agency on Aging helps older adults of west central Ohio remain in their homes with independence and dignity. We are an independent, private, nonprofit corporation that plans and funds services for older persons in Champaign, Clark, Darke, Greene, Logan, Miami, Montgomery, Preble, and Shelby Counties.

Read more:
Resolve to take charge of diabetes - The Daily Advocate

Read More...

Maternal diabetes in pregnancy tied to heart disease in adult kids – Reuters

December 12th, 2019 4:52 pm

(Reuters Health) - People whose mothers had diabetes during pregnancy may be at increased risk of developing cardiovascular disease by early adulthood, a recent study suggests.

The analysis followed more than 2.4 million babies born in Denmark for up to four decades, including nearly 55,000 whose mothers had diabetes during pregnancy. During the study period, cardiovascular disease developed before age 40 in 1,153 people whose mothers had diabetes while pregnant and 91,311 whose mothers did not.

When mothers had diabetes during pregnancy, their offspring were 29% more likely to develop cardiovascular disease, researchers report in The BMJ.

Preventing, screening and treating diabetes in women of childbearing age may be important not only for improving health of the women but also for reducing long-term cardiovascular disease risks in their offspring, said study leader Yongfu Yu of Aarhus University in Denmark.

We also need to monitor cardiovascular disease risks in offspring of diabetic mothers and investigate possible life-course interventions that may reduce the occurrence of cardiovascular disease, Yu said by email.

A total of 26,272 infants were born to mothers who had gestational diabetes, which develops during pregnancy and usually disappears after the pregnancy is over.

Another 22,055 babies were exposed to their mothers type 1 diabetes, which typically develops in childhood or young adulthood when the pancreas cant produce insulin.

And 6,537 infants were exposed to maternal type 2 diabetes, which is linked to overweight and aging and happens when the body cant properly use insulin to convert blood sugar into energy.

Gestational diabetes was associated with a 19% higher risk of cardiovascular disease in early adulthood for the children, while exposure to maternal type 1 or type 2 diabetes was tied to a 34% greater risk of cardiovascular disease for the young adult children.

The study wasnt designed to determine whether maternal diabetes causes cardiovascular disease or hastens its development in offspring.

The children exposed in utero to maternal diabetes were also more likely to have parents with a history of cardiovascular disease, and to have higher rates as adults of obesity, high blood pressure, high cholesterol, chronic kidney disease - and diabetes, which is itself a powerful risk factor for heart disease.

Yu noted that pregnant women with diabetes have more glucose, or sugars, in the placenta, which may lead developing babies to produce more insulin and have higher levels of blood sugar while theyre in the womb. That, in turn, could potentially lead to changes in blood vessel function later in life that contribute to cardiovascular disease.

We have known for a while that children born to women with diabetes, including both diabetes before pregnancy as well as gestational diabetes, have a higher rate of important complications early in life including macrosomia (babies that are too large sometimes resulting in difficult deliveries), a higher rate of congenital malformations, more frequent admission to NICU because of babies having difficulties regulating their own blood sugar levels, to name a few, said Dr. Jorge Chavarro of the Harvard T.H. Chan School of Public Health in Boston.

These babies are known to have higher risks for being overweight or obese in childhood, and recent work has also suggested theyre at higher risk of cardiovascular and metabolic diseases as adults based on risk factors like levels of sugar and fats in the blood, said Chavarro, who wasnt involved in the study. This new study, he said by email, provides evidence that maternal diabetes can also result in a higher frequency of clinically relevant cardiovascular events during the first four decades of life.

SOURCE: bit.ly/2PBOV8h The BMJ, online December 4, 2019.

The rest is here:
Maternal diabetes in pregnancy tied to heart disease in adult kids - Reuters

Read More...

For sale: Long-acting PhIII GLP-1 diabetes drug that’s way behind rivals, now spurned by Sanofi – Endpoints News

December 12th, 2019 4:52 pm

Earlier on Monday, new Sanofi CEO Paul Hudson baited the hook on his upcoming strategy presentation Tuesday with a tell-tale deal to buy Synthorx for $2.5 billion. That fits squarely with hints that hes pointing the company to a bigger future in oncology, which also squares with a major industry tilt.

In a big reveal later in the day, though, Hudson offered a slate of stunners on his plans to surgically dissect and reassemble the portfoloio, saying that the company is dropping cardio and diabetes research which covers two of its biggest franchise arenas. Sanofi missed the boat on developing new diabetes drugs, and now its pulling out entirely. As part of the pullback, its dropping efpeglenatide, their once-weekly GLP-1 injection for diabetes.

To be out of cardiovascular and diabetes is not easy for a company like ours with an incredibly proud history, Hudson said on a call with reporters, according to the Wall Street Journal. As tough a choice as that is, were making that choice.

Unlock this story instantly and join 67,500+ biopharma pros reading Endpoints daily and it's free.

SUBSCRIBE SIGN IN

Read this article:
For sale: Long-acting PhIII GLP-1 diabetes drug that's way behind rivals, now spurned by Sanofi - Endpoints News

Read More...

Significant Effect of Diamyd in Type 1 Diabetes Shown in a New Comprehensive Analysis of Previous Phase III and Phase II Trials – PRNewswire

December 12th, 2019 4:52 pm

STOCKHOLM, Dec. 12, 2019 /PRNewswire/ -- Diamyd Medical announces that a new analysis based on data from more than 530 individual patients from previous phase III and II trials in Europe and US with the diabetes vaccine Diamyd has identified genetically defined subgroups of type 1 diabetes patients that show a positive and statistically significant dose-dependent treatment response.

In the analysis, patients who were positive for certain HLA genotypes and treated with the highest number of doses of Diamyd (three and four subcutaneous injections) experienced a statistically significant treatment effect of approximately 60% compared to placebo at 15 months from baseline. Also, when treatments with low number and high number dose regimens (two, three and four subcutaneous doses) were combined, a statistically significant treatment effect of approximately 40% was seen.

"This has great significance for Diamyd Medical, type 1 diabetes research and the antigen-specific immunotherapy field in general", says Mark Atkinson, Professor and Board member of Diamyd Medical. "These results support the notion that you can identify patients that will have a much higher likelihood to respond to a GAD-based therapy based on a well-known and scientifically plausible genetic profile. This finding has implications for both disease prevention as well as intervention trials in type 1 diabetes. I am encouraged that we are poised to advance a safe, specific and efficious treatment that has the potential to signifcantly change the course of this disease."

"The importance of today's announcement cannot be understated," says Ulf Hannelius, CEO of Diamyd Medical. "This finding strengthens the likelihood of success for the diabetes vaccine Diamyd and will be taken into account in the analysis of the ongoing DIAGNODE-2 trial. Notably, in the phase IIb trial DIAGNODE-2 we are advancing intralymphatic administration of Diamyd which we forsee to be even more efficacious than the subcutaneous route used in previous trials."

Professor Johnny Ludvigsson, Principal Investigator for the analysed Swedish Phase II and European Phase III trials and for the ongoing Phase IIb trial DIAGNODE-2 trial underlines the importance of these findings: "This may be a break through step towards understanding how personalized medicine for autoimmune diseases will evolve. It is a great achievment to for the first time be able to identify a large cohort of patients that experience a significant effect of autoantigen-specific treatment."

The analysis is based on data from more than 530 patients from three previously published trials: a European phase III trial, a Swedish phase II trial and a US phase II trial. The group showing the strongest response to the GAD-specific immunotherapy Diamyd represented approximately 25% of the total number of patients involved in the analysis. Also, a more broadly defined responder subgroup, representing approximately 50% of the total number of patients, showed a statistically significant treatment response. The results will be submitted as an abstract to a scientific conference and are based on a collaborative effort between Diamdy Medical, academic researchers and clinicians.

About Diamyd Medical

Diamyd Medical develops the diabetes vaccine Diamyd, as an antigen-specific immunotherapy for the preservation of endogenous insulin production. Diamyd has demonstrated good safety in trials encompassing more than 1,000 patients as well as effect in some pre-specified subgroups. Besides the Company's own European Phase IIb trial DIAGNODE-2 where the diabetes vaccine is administered directly into a lymph node, two investigator initiated clinical trials are ongoing with Diamyd. Diamyd Medical also develops the GABA-based investigational drug Remygen for regeneration of endogenous insulin production. An investigator-initiated Remygen trial in patients living with type 1 diabetes for more than five years is ongoing at Uppsala University Hospital. Diamyd Medical is one of the major shareholders in the stem cell company NextCell Pharma AB and has holdings in the medtech company Companion Medical, Inc., San Diego, USA.

Diamyd Medical's B-share is traded on Nasdaq First North Growth Market under the ticker DMYD B. FNCA Sweden AB is the Company's Certified Adviser; phone: +46 8-528 00 399, e-mail: info@fnca.se.

CONTACT:

For further information, please contact: Ulf Hannelius, President and CEOPhone: +46 736 35 42 41E-mail: ulf.hannelius@diamyd.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/diamyd-medical-ab/r/significant-effect-of-diamyd--in-type-1-diabetes-shown-in-a-new-comprehensive-analysis-of-previous-p,c2989690

The following files are available for download:

SOURCE Diamyd Medical AB

Continued here:
Significant Effect of Diamyd in Type 1 Diabetes Shown in a New Comprehensive Analysis of Previous Phase III and Phase II Trials - PRNewswire

Read More...

Page 795«..1020..794795796797..800810..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick